The association between HLA-B*15:02 and phenytoin-induced severe cutaneous adverse reactions: a meta-analysis.
Huong Thanh PhungKhanh Ngoc Cong DuongMac Ardy Junio GloriaThien Khac NguyenPublished in: Pharmacogenomics (2021)
Aim: Phenytoin (PHT) is a common anticonvulsant agent known for inducing severe cutaneous adverse reactions (SCARs). HLA-B*15:02 as a risk factor of PHT-induced SCARs was reported in numerous studies with inconsistent results. This meta-analysis aimed to establish pooling evidence of this association. Materials & methods: Pooled odds ratios (ORs) with 95% CIs were estimated using a random-effects model. Results: A total of 11 studies on 1389 patients, were included for the analyses. There was a significant association between HLA-B*15:02 and PHT-induced SCAR (pooled OR = 2.29, 95% CI: 1.25-4.19, p = 0.008). Furthermore, there was a significant association regarding Stevens-Johnson syndrome/toxic epidermal necrolysis (OR = 3.63, 95% CI: 2.15-6.13, p < 0.001) but no association regarding drug reaction with eosinophilia and systemic symptom. Conclusion: The results supported the recommendations of HLA-B*15:02 screening before treatment with PHT.
Keyphrases
- drug induced
- high glucose
- diabetic rats
- systematic review
- case control
- end stage renal disease
- newly diagnosed
- early onset
- risk factors
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- endothelial cells
- case report
- prognostic factors
- peritoneal dialysis
- clinical trial
- platelet rich plasma
- combination therapy